Legal status · Australia
Is Ginsenoside Rg3 legal in Australia?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
Ginsenoside Rg3 can be sold in Australia as a supplement or cosmetic ingredient, classified as "Available as a supplement / complementary medicine". That is not drug approval: TGA has not evaluated any health claim, and injectable or "research use only" versions fall outside supplement rules, so that label does not make human use lawful. On the evidence, 2 human studies are cited on its profile.
Ginsenoside Rg3 in Australia at a glance
| Classification | Available as a supplement / complementary medicine |
|---|---|
| TGA approval status | Not a TGA drug approval; sold as a supplement or cosmetic |
| Human studies cited | 2 of 5 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Ginsenoside Rg3 profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
Ginsenoside Rg3 can be sold in Australia as a supplement, food or cosmetic ingredient under the classification above, without drug approval.
- 02
Supplement status means TGA has not evaluated any health claim; manufacturers are responsible for safety and labeling, and quality varies by product.
- 03
Injectable or "research use only" versions are not supplements. That label does not make human use lawful, and injectables fall under medicines rules.
What Ginsenoside Rg3 is
A ginseng saponin whose effect on senescence runs in both directions depending on the cell: it reversed replicative senescence in human fibroblasts in culture and is studied as a senescence inducer in tumour cells. The only human data are pharmacokinetic.
Ginsenoside Rg3 is a triterpenoid saponin from Panax ginseng, studied mainly in China and Korea. Its senescence literature is cell culture.
Mechanism: In cultured human fibroblasts, 20(S)-Rg3 restored ATP and the NAD+ to NADH ratio, downregulated PI3K and Akt through mTOR inhibition with p53 and p21 involvement, and activated sirtuin 3 and PGC1alpha to stimulate mitochondrial biogenesis; the 20(R) stereoisomer did not. In astrocyte culture, Rg3 suppressed interleukin 6 and interleukin 8 via NF-kappaB and p38 MAPK, a senomorphic action.
Regulatory history: Not approved for any indication in the United States. Sold as a ginseng-derived supplement ingredient. No senescence or ageing trial is registered.
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Ginsenoside Rg3 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Ginsenoside Rg3 in other countries
Frequently asked questions
Is Ginsenoside Rg3 legal in Australia?
Ginsenoside Rg3 can be sold in Australia as a supplement or cosmetic ingredient, classified as "Available as a supplement / complementary medicine". That is not drug approval: TGA has not evaluated any health claim, and injectable or "research use only" versions fall outside supplement rules, so that label does not make human use lawful. On the evidence, 2 human studies are cited on its profile.
Can I buy Ginsenoside Rg3 in Australia?
Yes, in supplement or cosmetic form. In Australia Ginsenoside Rg3 is classified as "Available as a supplement / complementary medicine", so oral, topical or cosmetic products can be sold under supplement rules. Injectable versions and products labeled "research use only" are not supplements and are not approved for human use.
Is Ginsenoside Rg3 TGA approved?
No. In Australia Ginsenoside Rg3 is classified as "Available as a supplement / complementary medicine", which is not a TGA marketing approval. For comparison, the US FDA status is: Not approved for any indication in the United States. Sold as a ginseng-derived supplement ingredient. No senescence or ageing trial is registered.. On the evidence, 2 human studies are cited on its profile.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Ginsenoside Rg3 live on its compound profile.
Ginsenoside Rg3 profileThis page is general information about the regulatory status of Ginsenoside Rg3 in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.